The Protein Myth: Our Obsession With Protein and How It Is Killing US

Houston Methodist

G. Davis

Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

Health of Vegetarians and Vegans: Findings From EPIC-Oxford and Othe…

Physicians Committee for Responsible Medicine

T. J. Key

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

The GOOD and the BAD Side of GLP-1s and What to Do If You Get Caught…

Endocrinology 2024 Year in Review

Weightloss in Menopause

Susan Brian

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

Is There a Future for HbA1c? (Moving Towards CGM: GMI and TIR)

Practical Ways to Achieve Targets in Diabetes Care

I. Hirsch

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

University of Colorado Department of Medicine

R. Johnson

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

Labs to Check on Semaglutide or Tirzepatide

Susan Brian

Hypertension 2025: New Guidelines and Resistant Hypertension

University of Louisville

K. Ferdinand

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

Heart Failure in Women: 2025 Update

Scripps Health

M. Kittleson

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

Tirzepatide Updates

Diana Isaacs

Could GLP-1's be a 'Game Changer' For Weight Loss? Can it be a Safer…

Ken Fujioka